Model Description

EAE is induced following the immunization of animals with MOG 35-55 peptide in complete Freund's adjuvant and the concomitant administration of Pertussis Toxin. The symptoms of the disease manifest with progressive paralysis and the first signs appear 10 days following the initial immunization.

 Preclinical efficacy evaluation

Study design

An EAE study in huTNFR1KI mice is normally completed  35 days after MOG immunization. Incidence ranges from 80-100%. A standard protocol involves a therapeutic regimen with administration of therapeutics starting at day 8-10, when pathology has already started developing. 

Read-out parameters

• In-vivo EAE scoring

• Body weight measurements

Figure 1: huTNFR1KI animals immunized with MOG develop signs of paralysis starting at day 10, with symptoms subside following anti-huTNFR1 treatment.

 

Bibliography

1. Kassiotis G, Kollias G. 2001 "Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination", J Exp Med. 193, 427-34.